RAS and ROS in Rhabdomyosarcoma
Menée à l'aide de xénogreffes, cette étude met en évidence l'intérêt de cibler la signalisation du stress oxydant pour le traitement d'un rhabdomyosarcome de type embryonnaire
The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.
Cancer cell , commentaire, 2012